Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Defining EGFR amplification status for clinical trial inclusion

23 May 2019

Abstract excerpt

BACKGROUND: Precision medicine trials targeting the epidermal growth factor receptor (EGFR) in glioblastoma patients require selection for EGFR-amplified tumors. However, there is currently no gold standard in determining the amplification status of EGFR or variant III (EGFRvIII) expression. Here, we aimed to determine which technique and which cutoffs are suitable to determine EGFR amplification status. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Glioma Diagnosis and Treatment
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31125418
DOI: 10.1093/neuonc/noz096

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Defining EGFR amplification status for clinical trial inclusionPMID 31125418Read ↗

Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with GlioblastomaSemantic proximity Read ↗

Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastomaSemantic proximity Read ↗

Molecular pathologic diagnosis of epidermal growth factor receptor.Semantic proximity Read ↗

Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.Semantic proximity Read ↗

Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastomaSemantic proximity Read ↗

Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumorsSemantic proximity Read ↗

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay.Semantic proximity Read ↗

A case of glioblastoma harboring non-amplified epidermal growth factor receptor variant III: Critical molecular detection using RNA-based panel analysis.Semantic proximity Read ↗

An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathologySemantic proximity Read ↗

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC.Semantic proximity Read ↗

<i>HER2</i> Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical TrialsSemantic proximity Read ↗

Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.